These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 22300559

  • 1. Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy.
    Whaley JT, Levy LB, Swanson DA, Pugh TJ, Kudchadker RJ, Bruno TL, Frank SJ.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):e765-71. PubMed ID: 22300559
    [Abstract] [Full Text] [Related]

  • 2. Erectile function after prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH, Allen ZA.
    Int J Radiat Oncol Biol Phys; 2005 Jun 01; 62(2):437-47. PubMed ID: 15890585
    [Abstract] [Full Text] [Related]

  • 3. Erectile function after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Galbreath RW, Stipetich RL, Abel LJ, Lief JH.
    Int J Radiat Oncol Biol Phys; 2002 Mar 15; 52(4):893-902. PubMed ID: 11958881
    [Abstract] [Full Text] [Related]

  • 4. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction.
    Merrick GS, Butler WM, Wallner KE, Lief JH, Anderson RL, Smeiles BJ, Galbreath RW, Benson ML.
    Int J Radiat Oncol Biol Phys; 2002 Nov 15; 54(4):1055-62. PubMed ID: 12419431
    [Abstract] [Full Text] [Related]

  • 5. Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil.
    Pugh TJ, Mahmood U, Swanson DA, Munsell MF, Wang R, Kudchadker RJ, Bruno TL, Frank SJ.
    Brachytherapy; 2015 Nov 15; 14(2):160-5. PubMed ID: 25255712
    [Abstract] [Full Text] [Related]

  • 6. Long-term potency preservation following brachytherapy for prostate cancer.
    Snyder KM, Stock RG, Buckstein M, Stone NN.
    BJU Int; 2012 Jul 15; 110(2):221-5. PubMed ID: 22734475
    [Abstract] [Full Text] [Related]

  • 7. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy.
    Solan AN, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Apr 01; 73(5):1468-74. PubMed ID: 18922652
    [Abstract] [Full Text] [Related]

  • 8. Potency preservation following stereotactic body radiation therapy for prostate cancer.
    Obayomi-Davies O, Chen LN, Bhagat A, Wright HC, Uhm S, Kim JS, Yung TM, Lei S, Batipps GP, Pahira J, McGeagh KG, Collins BT, Kowalczyk K, Bandi G, Kumar D, Suy S, Dritschilo A, Lynch JH, Collins SP.
    Radiat Oncol; 2013 Nov 01; 8():256. PubMed ID: 24180317
    [Abstract] [Full Text] [Related]

  • 9. Erectile function durability following permanent prostate brachytherapy.
    Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Kurko BS, Anderson R, Lief JH.
    Int J Radiat Oncol Biol Phys; 2009 Nov 01; 75(3):639-48. PubMed ID: 19303721
    [Abstract] [Full Text] [Related]

  • 10. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction.
    Merrick GS, Wallner K, Butler WM, Galbreath RW, Lief JH, Benson ML.
    Int J Radiat Oncol Biol Phys; 2001 Jul 01; 50(3):597-604. PubMed ID: 11395225
    [Abstract] [Full Text] [Related]

  • 11. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important?
    Macdonald AG, Keyes M, Kruk A, Duncan G, Moravan V, Morris WJ.
    Int J Radiat Oncol Biol Phys; 2005 Sep 01; 63(1):155-63. PubMed ID: 16111584
    [Abstract] [Full Text] [Related]

  • 12. Dose to the penile bulb and individual patient anatomy are predictive of erectile dysfunction in men treated with 125I low dose rate brachytherapy for localized prostate cancer.
    Chasseray M, Dissaux G, Bourbonne V, Boussion N, Goasduff G, Malloreau J, Malhaire JP, Fournier G, Tissot V, Pradier O, Valeri A, Schick U.
    Acta Oncol; 2019 Jul 01; 58(7):1029-1035. PubMed ID: 30761939
    [Abstract] [Full Text] [Related]

  • 13. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years.
    Stone NN, Stock RG.
    Urology; 2007 Feb 01; 69(2):338-42. PubMed ID: 17320674
    [Abstract] [Full Text] [Related]

  • 14. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).
    Mangar SA, Sydes MR, Tucker HL, Coffey J, Sohaib SA, Gianolini S, Webb S, Khoo VS, MRC RT01 Trial Management Group, Dearnaley DP.
    Radiother Oncol; 2006 Sep 01; 80(3):355-62. PubMed ID: 16949694
    [Abstract] [Full Text] [Related]

  • 15. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
    Nobes JP, Khaksar SJ, Hawkins MA, Cunningham MJ, Langley SE, Laing RW.
    Radiother Oncol; 2008 Jul 01; 88(1):121-6. PubMed ID: 18499289
    [Abstract] [Full Text] [Related]

  • 16. A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Matsushima M, Kikuchi E, Maeda T, Nakashima J, Sugawara A, Ando T, Mizuno R, Nagata H, Miyajima A, Shigematsu N, Oya M.
    J Urol; 2013 Mar 01; 189(3):1014-8. PubMed ID: 23017516
    [Abstract] [Full Text] [Related]

  • 17. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer.
    Stock RG, Stone NN, Iannuzzi C.
    Int J Radiat Oncol Biol Phys; 1996 May 01; 35(2):267-72. PubMed ID: 8635932
    [Abstract] [Full Text] [Related]

  • 18. Five-year potency preservation after iodine-125 prostate brachytherapy.
    Nishimura S, Yorozu A, Ohashi T, Sakayori M, Yagi Y, Nishiyama T, Saito S, Shiraishi Y, Yoshida K, Toya K, Shigematsu N.
    Int J Clin Oncol; 2014 Oct 01; 19(5):940-5. PubMed ID: 24170247
    [Abstract] [Full Text] [Related]

  • 19. Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer.
    Peng LC, Mian OY, Lakshminarayanan P, Huang P, Bae HJ, Robertson S, Habtu T, Narang A, Agarwal S, Greco S, Tran P, McNutt T, DeWeese TL, Song DY.
    Urology; 2020 Jan 01; 135():111-116. PubMed ID: 31454660
    [Abstract] [Full Text] [Related]

  • 20. Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Okihara K, Yorozu A, Saito S, Tanaka N, Koga H, Higashide S, Kikuchi T, Nakano M.
    Int J Urol; 2017 Jul 01; 24(7):518-524. PubMed ID: 28455847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.